Dublin, Ireland, and Columbia, MD, USA, 17 March 2008 - AGI Therapeutics plc (“AGI” or the “Company”), a specialty pharmaceuticals company focused on gastrointestinal drug products, today announces the completion of the optimisation phase of development of AGI-010, a modified release formulation of the proton pump inhibitor drug (“PPI”) omeprazole which utilizes AGI’s CHRONAB technology.
